A Phase Ic, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Activity of Inhaled GDC-6988 in Patients With Muco-Obstructive Disease
Latest Information Update: 29 Nov 2024
Price :
$35 *
At a glance
- Drugs ETD 002 (Primary)
- Indications Bronchiectasis; Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors Genentech
- 26 Nov 2024 Status changed from not yet recruiting to recruiting.
- 01 Oct 2024 New trial record